Roivant Sciences Ltd.
ROIV
Pozycja w akcjach
#979
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company... Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
Cena akcji
$33.73
Ostatnia synchronizacja: 2026-07-31
Kapitalizacja rynkowa
$24.37B
Zmiana (1 dzień)
-2.28%
Zmiana (1 rok)
90.15%
Kraj
GB
Handel Roivant Sciences Ltd. (ROIV)
Kategoria
Healthcare
Zyski dla Roivant Sciences Ltd. (ROIV)
Zyski w Jun 2026 TTM: $-289.88M
Według najnowszych raportów finansowych Roivant Sciences Ltd., obecny zysk firmy wynosi $-289.88M. W roku 2024 firma osiągnęła zysk w wysokości $4.57B, wzrost w porównaniu do zysku z roku 2023, który wynosił $-1.22B. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy Roivant Sciences Ltd. od 2020 do 2026
Zyski na koniec każdego roku
| Rok | Zyski | Zmień |
|---|---|---|
| 2026 (TTM) | $-289.88M | -57.47% |
| 2025 | $-681.59M | -114.92% |
| 2024 | $4.57B | -472.94% |
| 2023 | $-1.22B | 32.59% |
| 2022 | $-923.75M | 2.80% |
| 2021 | $-898.55M | 60.17% |
| 2020 | $-560.99M | 0.00% |
Zyski podobnych firm lub konkurentów
| Firma | Zyski | Różnica w zyskach | Kraj |
|---|---|---|---|
| $5.27B | -1,919.68% |
US
|
|
| $-3.09B | 964.92% |
US
|
|
| $-4.02B | 1,285.47% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -772.92% |
NL
|
